ライフサイエンスコーパス: hemolytic

1 elices that are biologically promiscuous and hemolytic.

2 The cytotoxic and hemolytic activities of the AMPs against human cells and

3 with dual 2'-O-methytransferase and putative hemolytic activities.

4 protein, a molecular mass of 2.4kDa and low hemolytic activity (<50% hemolysis of human erythrocytes

5 Ply hemolytic activity against human RBCs showed dose-depend

6 zole hybrids, their time-kill studies, their hemolytic activity against murine erythrocytes, as well

7 also has glycan-binding properties and that hemolytic activity against RBCs can be blocked with the

8 ng residues of Ply resulted in a decrease in hemolytic activity and a reduced affinity for sLeX.

9 An hns mutant exhibited increased hemolytic activity and cytotoxicity compared to the wild

10 is responsible for the previously described hemolytic activity associated with the choA orthologue i

11 e, one VHH heterodimer could reduce Shigella hemolytic activity by >80%.

12 erent C5 inhibitors simultaneously, residual hemolytic activity could be abolished.

13 up, the corresponding decrease in complement hemolytic activity distinguished survivors from nonsurvi

14 lls for at least 96 h continuous exposure or hemolytic activity even at 20 mg/ml.

15 umolysin, which is associated with increased hemolytic activity in ST3081 and may contribute to incre

16 ases in the DeltavfrB mutant did not restore hemolytic activity in the DeltavfrB mutant on blood agar

17 The hemolytic activity is abrogated in mutants that disrupt

18 nding that Rv0888 accounts for half of Mtb's hemolytic activity is consistent with its sphingomyelina

19 Here, we detected a stronger hemolytic activity mediated by ILY when S. intermedius P

20 Conversely, the hemolytic activity of CfTX-A/B (HU50 = 5 ng ml(-1)) was

21 C resulting in significant inhibition of the hemolytic activity of human serum.

22 Here, we used the hemolytic activity of LLO as a phenotypic marker to scre

23 Hemolytic activity of strains missing either cccB or res

24 in Cytolysin A (ClyA) is responsible for the hemolytic activity of various Escherichia coli and Salmo

25 gative and Gram-positive bacteria, while its hemolytic activity remained around 10% or less, even aft

26 osteoblast and Caco-2 epithelial cells, and hemolytic activity was assessed on rabbit erythrocytes a

27 ured in human plasma, no similar increase in hemolytic activity was observed.

28 e than 1000 phosphate units suppressed total hemolytic activity with a concentration to reduce maxima

29 e polar, uncharged subunits can diminish the hemolytic activity with minimal impact on the antibacter

30 s with eukaryotic cells, as evidenced by low hemolytic activity, and protects the polypeptide backbon

31 Hemolytic activity, colonization, and virulence of S. pn

32 n of the lectin domain seriously compromises hemolytic activity, it is thought that carbohydrate-depe

33 utant expressing this mutation retained full hemolytic activity.

34 and is required for normal cytotoxicity and hemolytic activity.

35 o showed cytotoxicity against Vero cells and hemolytic activity.

36 l activity but causes significant changes in hemolytic activity.

37 nse during macrophage infection, and loss of hemolytic activity.

38 rom IPF patients showed significantly higher hemolytic activity.

39 ited proteolytic stability, with no apparent hemolytic activity.

40 vancomycin-resistant Enterococci as well as hemolytic activity.

41 ate that exposure of cultured macrophages to hemolytic aged red blood cells, heme, or iron causes the

42 HBBE6V; HbSS), plasma EPO is elevated due to hemolytic anaemia-related hypoxia.

43 ts reveal that VG16KRKP, a non-toxic and non-hemolytic analogue of VG16, shows significant antimicrob

44 rCsMAP34 stimulated the hemolytic and bactericidal activities of serum complemen

45 cal pathway of complement activation in both hemolytic and complement deposition assays.

46 how that the monomeric preparation displayed hemolytic and cytotoxic activities suggesting that the m

47 against Gram-positive bacteria, but is also hemolytic and cytotoxic.

48 ium and Lactobacillus species), and were non-hemolytic and non-toxic to mammalian cell lines HepG2 an

49 y compared to W4A9, as quantified via ELISA, hemolytic, and cell-based assays, and showed improved so

50 activities, along with resistance/enzymatic, hemolytic, and cytotoxicity assays were also studied.

51 plasma as well as being hemocompatible (non-hemolytic, and poor activator of the complement system).

52 ve hemophagocytic syndrome (44%), autoimmune hemolytic anemia (33%), and lymphoma (22%) were the comm

53 ively investigated in 308 primary autoimmune hemolytic anemia (AIHA) cases and correlated with serolo

54 Autoimmune hemolytic anemia (AIHA) is an uncommon entity that prese

55 The development of warm-antibody autoimmune hemolytic anemia (also known as warm autoimmune hemolyti

56 zymopathies, known as chronic nonspherocytic hemolytic anemia (CNSHA).

57 zed by thrombocytopenia and microangiopathic hemolytic anemia (MAHA) without an obvious cause, and ma

58 actory thrombocytopenia (n = 13), autoimmune hemolytic anemia (n = 15), and vasculitis (n = 6).

59 olytic anemia (also known as warm autoimmune hemolytic anemia [WAHA]) in patients with babesiosis has

60 l pathways that can lead to microangiopathic hemolytic anemia and a procoagulant state with or withou

61 While hemolytic anemia and an altered cytokine environment hav

62 ll lymphoproliferation results in autoimmune hemolytic anemia and cold-induced circulatory symptoms.

63 ited blood disorder characterized by chronic hemolytic anemia and episodic vaso-occlusive pain crises

64 limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias.

65 substantial improvement of sickle-associated hemolytic anemia and reticulocytosis, key pathophysiolog

66 ion in blood cells, which is responsible for hemolytic anemia and skin photosensitivity.

67 ce was reflected in reduced pancreatitis and hemolytic anemia and this was associated with distinct c

68 gical hallmark of anti-GBM-GN, combined with hemolytic anemia and thrombocytopenia.

69 phlebotomy-induced acute anemia and chronic hemolytic anemia because of 4.1R deficiency, the ratio o

70 ies to treat not only chronic nonspherocytic hemolytic anemia caused by severe G6PD variants, but als

71 is (HX; MIM 194380) is an autosomal-dominant hemolytic anemia characterized by primary erythrocyte de

72 lmonary hypertension associated with chronic hemolytic anemia has been moved from Group 1 PAH to Grou

73 eferred second-line therapy of warm antibody hemolytic anemia in adults, although no prospective stud

74 is the primary molecular event that leads to hemolytic anemia in sickle cell disease (SCD).

75 cold agglutinin disease (CAD), an autoimmune hemolytic anemia in which autoantibodies (cold agglutini

76 Warm antibody hemolytic anemia is the most common form of autoimmune h

77 f red blood cells in human subjects, causing hemolytic anemia linked to impaired nicotinamide adenine

78 component of the management of warm antibody hemolytic anemia not only after relapse but as soon as t

79 Finally, we chemically induce hypoxemia via hemolytic anemia resulting in HIF stabilization within c

80 Sickle cell disease (SCD), a congenital hemolytic anemia that exacts terrible global morbidity a

81 genus babesia, is characterized by nonimmune hemolytic anemia that resolves with antimicrobial treatm

82 -phosphate dehydrogenase, exhibit non-immune hemolytic anemia upon exposure to aspirin and various an

83 Hemolytic anemia was stimulated by phenylhydrazine injec

84 eficiency are at risk for the development of hemolytic anemia when given 8-aminoquinolines (8-AQs), a

85 cantly impaired erythropoietic recovery from hemolytic anemia, acute blood loss and myeloablation.

86 ll spectrum HUS, including thrombocytopenia, hemolytic anemia, and AKI with glomerular thrombotic mic

87 SCD) results in vascular occlusions, chronic hemolytic anemia, and cumulative organ damage.

88 ing preexisting TTP signs; thrombocytopenia, hemolytic anemia, and organ damage could not be reversed

89 ection-site erythema and pyrexia, autoimmune hemolytic anemia, and suspected lack of vaccine efficacy

90 at emerge on erythrocytes lead to autoimmune hemolytic anemia, and the causative auto-IgM cross-react

91 in the liver also occurs in mouse models of hemolytic anemia, anemia of inflammation, and sickle cel

92 c disorder diagnosed by thrombocytopenia and hemolytic anemia, associated with a deficiency in von Wi

93 a gene mutated in Mendelian non-spherocytic hemolytic anemia, associated with HGB and HCT (SKAT p <

94 ong descriptive diagnoses such as autoimmune hemolytic anemia, chronic immune thrombocytopenia, Evans

95 immune thrombocytopenia and warm autoimmune hemolytic anemia, circulating immunoglobulin G (IgG)-ops

96 vere genetic blood disorder characterized by hemolytic anemia, episodic vaso-occlusion, and progressi

97 ng numerous clinical settings such as severe hemolytic anemia, infection, tissue injury, or blood tra

98 The phenotype of severe nonspherocytic hemolytic anemia, jaundice, hepatosplenomegaly, and mark

99 ets, which account for the thrombocytopenia, hemolytic anemia, schistocytes, and tissue injury that c

100 angiopathy characterized by microangiopathic hemolytic anemia, severe thrombocytopenia, and organ isc

101 tic link between the induction of autoimmune hemolytic anemia, the reduction in naive T cells, and po

102 remic syndrome is a disease characterized by hemolytic anemia, thrombocytopenia and acute renal failu

103 sel thrombosis resulting in microangiopathic hemolytic anemia, thrombocytopenia and renal failure.

104 surface level that leads to microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney fai

105 Microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney inj

106 condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and ARF.

107 hy that is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and renal failure.

108 marrow failure disorder that manifests with hemolytic anemia, thrombosis, and peripheral blood cytop

109 Using a murine model of autoimmune hemolytic anemia, we defined the contribution of galacto

110 anemia is the most common form of autoimmune hemolytic anemia.

111 by poor pharmacokinetics and toxicity due to hemolytic anemia.

112 erythrocyte Abs and is a model of autoimmune hemolytic anemia.

113 presented with severe, transfusion-dependent hemolytic anemia.

114 d commitment under stress conditions such as hemolytic anemia.

115 7(E11)Val --> Met) that were associated with hemolytic anemia.

116 ing AS treatment is an original mechanism of hemolytic anemia.

117 a disorder associated with acute or chronic hemolytic anemia.

118 rocytosis (HX) and/or undiagnosed congenital hemolytic anemia.

119 er affecting 15% of patients with autoimmune hemolytic anemia.

120 human AE1 cause several types of hereditary hemolytic anemias and/or distal renal tubular acidosis.

121 ematocrit, sickle cell disease, thalassemia, hemolytic anemias, and malaria, with both arterial and v

122 ase and other chronic hereditary or acquired hemolytic anemias.

123 tant driver of human disease, including many hemolytic anemias.

124 red cell membrane skeleton underlie multiple hemolytic anemias.

125 otective function of FH in sheep erythrocyte hemolytic assays and increase cell-surface C3b depositio

126 surface plasmon resonance (SPR) studies and hemolytic assays.

127 gram-negative bacilli and regular, grey non-hemolytic colonies appearing the next day on blood agar.

128 l activity of C5 can be screened using a 50% hemolytic complement (CH50) assay, which is sensitive to

129 , TMPMs that were devoid of any demonstrable hemolytic, cytotoxic, and antifungal activities chemosen

130 Although the prevention of hemolytic disease of the fetus and newborn is highly eff

131 aniofacial anomalies, chromosomal disorders, hemolytic disease, multiple gestation, third-trimester m

132 twin-twin transfusion, alloimmunization, and hemolytic disease.

133 Hemopexin protects against heme toxicity in hemolytic diseases and conditions, sepsis, and sickle ce

134 Hemolytic diseases are characterized by enhanced intrava

135 Hemolytic diseases include a variety of conditions with

136 he effects of free heme and free iron during hemolytic diseases such as sickle cell disease, dengue f

137 es (MPs) concentrate cell-free heme in human hemolytic diseases, and that heme-laden MPs have a physi

138 Hemolytic diseases, such as sickle cell anemia and thala

139 inemia cases in newborns are associated with hemolytic diseases, we emphasize here the impaired abili

140 due to malaria, sickle cell disease or other hemolytic diseases, will enable identification of high-r

141 e involved in the prevalent and debilitating hemolytic disorder sickle cell disease (SCD).

142 . Dacie was known for his pioneering work on hemolytic disorders, especially paroxysmal nocturnal hem

143 f HU as an acute treatment for SCD and other hemolytic disorders.

144 rapeutic targets for patients with sepsis or hemolytic disorders.

145 d in a 2.5- to 4.8-fold increase in the anti-hemolytic effect but this was undetected in chemical ass

146 Similarly, OVTX-a hemolytic effect is lower than that of the reference PLT

147 th artesunate sometimes experience a delayed hemolytic episode.

148 However, ribavirin is associated with hemolytic events and is poorly tolerated by some patient

149 with sickle cell disease (SCD), a prevalent hemolytic genetic disorder.

150 s (GBS) or Streptococcus agalactiae are beta-hemolytic gram-positive bacteria that colonize the lower

151 cci (GBS; Streptococcus agalactiae) are beta-hemolytic, Gram-positive bacteria that are common asympt

152 (GBS) or Streptococcus agalactiae is a beta-hemolytic, Gram-positive bacterium that is a leading cau

153 ity to detect Streptococcus group A and beta-hemolytic groups C/G using rapid antigen-negative pharyn

154 ta provide novel insights into mechanisms of hemolytic inflammation and further support perspectives

155 flammatory effects by inhibiting rapid-onset hemolytic inflammation via an NO-dependent mechanism, in

156 Relative hemolytic intensity was estimated from a composite index

157 nes (DARC) as the receptor for the S. aureus hemolytic leukocidins LukED and HlgAB.

158 ed that, irrespective of the stress-induced (hemolytic or post-erythropoietin [Epo]) treatment, only

159 Pseudomonas aeruginosa hemolytic phospholipase C (PlcH) degrades phosphatidylch

160 By reverse hemolytic plaque assay, we showed that glucose-stimulate

161 changed the PLYa of ST8 strain 6308 with the hemolytic PLY (PLYh) of ST3 A66.1 and vice versa and det

162 re every injection given to 22 patients with hemolytic PNH while receiving eculizumab therapy.

163 e animal model that can predict the clinical hemolytic potential of drugs.

164 activation on RBCs could play a role in the hemolytic process occurring during STEC-HUS.

165 is and whether complement is involved in the hemolytic process.

166 Analysis of the antibacterial and hemolytic properties of these mixtures revealed that sel

167 aim of improving antimicrobial activity and hemolytic properties, we use these reactivity difference

168 th hydroxyurea, known to decrease anemia and hemolytic rate.

169 TSAR2 overexpression specifically boosted hemolytic saponin biosynthesis, whereas TSAR1 overexpres

170 ca associated with a different strongly beta-hemolytic spirochete that has been molecularly and pheno

171 itis guidelines focus solely on group A beta-hemolytic streptococcal infection.

172 tis occurs more frequently than group A beta-hemolytic streptococcal-positive pharyngitis in a studen

173 The Lyra assay correctly detected all beta-hemolytic streptococci (group A, n = 19; group C/G, n =

174 ptococcus pneumoniae (n = 13; 21%), and beta-hemolytic Streptococci (n = 5; 8%).

175 r cellulitis without purulent drainage, beta-hemolytic streptococci are presumed to be the predominan

176 receptor in the single MPhi response to beta-hemolytic streptococci.

177 Rapid detection of group A beta-hemolytic streptococcus (GAS) is used routinely to help

178 ganisms are identified, most are due to beta-hemolytic Streptococcus and Staphylococcus aureus.

179 The pathogenic role of beta-hemolytic Streptococcus dysgalactiae in the equine host

180 Group A beta-hemolytic streptococcus was detected in 10.3% of patient

181 Group C/G beta-hemolytic streptococcus was detected in 9.0% of patients

182 The best polymer was less hemolytic than LL-37.

183 st promising compounds were found to be less hemolytic than the FDA-approved antifungal agent voricon

184 Also, they were both relatively less hemolytic than the known membrane targeting antibiotic g

185 ssing cells to ethidium bromide; and was non-hemolytic to human red blood cells.

186 Treatment with drugs known to cause hemolytic toxicity (pamaquine, sitamaquine, tafenoquine,

187 l to test drugs for their potential to cause hemolytic toxicity in G6PD-deficient populations.

188 Hemolytic transfusion reactions (HTRs) due to incompatib

189 antibodies against RBC non-ABO Ags can cause hemolytic transfusion reactions and limit availability o

190 s because p erythrocytes may pose a risk for hemolytic transfusion reactions due to their elevated PX

191 Thus, understanding of hemolytic transfusion reactions is generated through cli

192 Antibody-induced hemolytic transfusion reactions were first described ove

193 increase the probability of life-threatening hemolytic transfusion reactions, not all patients genera

194 inst RBCs can cause life-threatening delayed hemolytic transfusion reactions.

195 Collectively, our findings point to hemolytic type I E. coli as a candidate causative factor

196 Complement mediated hemolytic uremic syndrome (aHUS) accounts for a signific

197 inhibition therapy in patients with atypical hemolytic uremic syndrome (aHUS) are remarkable in contr

198 in, have been well characterized in atypical hemolytic uremic syndrome (aHUS) but have been less well

199 Patients with atypical hemolytic uremic syndrome (aHUS) develop a thrombotic mi

200 escribe an assay that could convert atypical hemolytic uremic syndrome (aHUS) from a diagnosis of exc

201 eneic HSCT shares similarities with atypical hemolytic uremic syndrome (aHUS) in the underlying patho

202 Atypical hemolytic uremic syndrome (aHUS) is a genetic ultrarare

203 Atypical hemolytic uremic syndrome (aHUS) is a genetic, life-thre

204 Atypical hemolytic uremic syndrome (aHUS) is a rare disease with

205 Atypical hemolytic uremic syndrome (aHUS) is a severe thrombotic

206 Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microan

207 Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microan

208 Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microan

209 Atypical hemolytic uremic syndrome (aHUS) is an orphan disease wi

210 Atypical hemolytic uremic syndrome (aHUS) is characterized by com

211 Atypical hemolytic uremic syndrome (aHUS) is characterized by dys

212 Atypical hemolytic uremic syndrome (aHUS) is characterized by gen

213 Atypical hemolytic uremic syndrome (aHUS) is classically describe

214 The pathogenesis of atypical hemolytic uremic syndrome (aHUS) is strongly linked to d

215 Atypical hemolytic uremic syndrome (aHUS) is usually characterize

216 ions in complement C3 identified in atypical hemolytic uremic syndrome (aHUS) patients cause dysregul

217 he thrombotic microangiopathy (TMA) atypical hemolytic uremic syndrome (aHUS) resulted in the success

218 iseases C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS) strongly associate with

219 ave been described in patients with atypical hemolytic uremic syndrome (aHUS), a rare condition chara

220 Atypical hemolytic uremic syndrome (aHUS), a rare form of thrombo

221 h was described in association with atypical hemolytic uremic syndrome (aHUS), also confers high risk

222 ed CFH, whereas R53H-CFH, linked to atypical hemolytic uremic syndrome (aHUS), was defective in C3bBb

223 s is central to the pathogenesis of atypical hemolytic uremic syndrome (aHUS).

224 tic microangiopathy (TMA), known as atypical hemolytic uremic syndrome (aHUS).

225 nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

226 hrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS) are appropriately at the

227 Hemolytic uremic syndrome (HUS) caused by intestinal Shi

228 104:H4 caused an outbreak with >800 cases of hemolytic uremic syndrome (HUS) in Germany, including 90

229 Hemolytic uremic syndrome (HUS) is a thrombotic microang

230 Hemolytic uremic syndrome (HUS) is the life-threatenig s

231 Hemolytic uremic syndrome (HUS) occurred in 12 patients

232 Of the 62 individuals with diarrheal hemolytic uremic syndrome (HUS) seen at our institution

233 e offending agent of postdiarrhea-associated hemolytic uremic syndrome (HUS), a disorder of glomerula

234 tion status, the development and severity of hemolytic uremic syndrome (HUS), and adverse outcomes in

235 e progresses to hemorrhagic colitis (HC) and hemolytic uremic syndrome (HUS), due to the expression o

236 role in the pathogenesis of postenteropathic hemolytic uremic syndrome (HUS), most commonly caused by

237 moxetumomab pasudotox for 10 doses developed hemolytic uremic syndrome (HUS), thrombotic microangiopa

238 survival outcomes of waitlisted adults with hemolytic uremic syndrome (HUS).

239 Stx)-producing Escherichia coli (STEC) cause hemolytic uremic syndrome (HUS).

240 a serious kidney-damaging sequela called the hemolytic uremic syndrome (HUS).

241 ix cases were hospitalized, including 4 with hemolytic uremic syndrome (HUS).

242 hea, dysentery, hemorrhagic colitis (HC) and hemolytic uremic syndrome (HUS).

243 infection is associated with development of hemolytic uremic syndrome (HUS).

244 to severe renal diseases, including atypical hemolytic uremic syndrome and C3 glomerulopathies, and a

245 associated with the renal diseases atypical hemolytic uremic syndrome and dense deposit disease and

246 lation-mediated endothelial damage: atypical hemolytic uremic syndrome and thrombotic thrombocytopeni

247 the basis of clinical presentation (atypical hemolytic uremic syndrome as thrombotic microangiopathy)

248 afety of anticomplement therapy for atypical hemolytic uremic syndrome during pregnancy, and implicat

249 We report a case of hemolytic uremic syndrome in a 69-year-old woman due to

250 Hemolytic uremic syndrome is a disease characterized by

251 FHR) genes and autoantibody-positive form of hemolytic uremic syndrome is characterized by the presen

252 evelop a life-threatening sequela called the hemolytic uremic syndrome is unpredictable.

253 011 Shiga toxin-producing E. coli-associated hemolytic uremic syndrome outbreak in Germany, critical

254 rne pathogen that causes bloody diarrhea and hemolytic uremic syndrome throughout the world.

255 In hemolytic uremic syndrome with brain involvement symptom

256 ny outbreaks of gastrointestinal illness and hemolytic uremic syndrome worldwide.

257 The Oklahoma TTP-HUS (hemolytic uremic syndrome) Registry enrolled 70 consecut

258 Hemolytic uremic syndrome, a life-threatening disease of

259 tations in FH and MCP are linked to atypical hemolytic uremic syndrome, a type of thrombotic microang

260 g age-related macular degeneration, atypical hemolytic uremic syndrome, and C3 glomerulopathies.

261 e-specific diseases such as AMD and atypical hemolytic uremic syndrome, and leads to a better underst

262 these genes have been described in atypical hemolytic uremic syndrome, arising commonly through nona

263 nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome, blocks the terminal complemen

264 sent in patients with the autoimmune form of hemolytic uremic syndrome, is involved in B cell regulat

265 E. coli O157:H7 can cause bloody diarrhea, hemolytic uremic syndrome, or even death.

266 a spectrum of rare diseases such as atypical hemolytic uremic syndrome, thrombotic thrombocytopenic p

267 Compared with wild type FH19-20, atypical hemolytic uremic syndrome-associated mutants were less a

268 h preventive or therapeutic ends, for use in hemolytic uremic syndrome-endemic areas or during future

269 renal biopsy of a child with EHEC-associated hemolytic uremic syndrome.

270 sease, including hemorrhagic colitis and the hemolytic uremic syndrome.

271 induced by sera from patients with atypical hemolytic uremic syndrome.

272 nary tract infections, as well as sepsis and hemolytic uremic syndrome.

273 mplications, such as hemorrhagic colitis and hemolytic uremic syndrome.

274 rne pathogen causing hemorrhagic colitis and hemolytic uremic syndrome.

275 infection, and disseminated malignancy or in hemolytic uremic syndrome.

276 with eculizumab after a relapse of atypical hemolytic uremic syndrome.

277 okine, interleukin-1beta, has been linked to hemolytic uremic syndrome.

278 pathogen that causes hemorrhagic colitis and hemolytic uremic syndrome.

279 -1 cells, an experimental model for atypical hemolytic uremic syndrome.

280 d in the development of the life-threatening hemolytic uremic syndrome.

281 eadly thrombomicroangiopathy called atypical hemolytic uremic syndrome.

282 xysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

283 aging findings in a four-month-old male with hemolytic uremic syndrome.

284 Atypical hemolytic-uremic syndrome (aHUS) is associated with gene

285 Hemolytic-uremic syndrome (HUS) features episodes of sma

286 Hemolytic-uremic syndrome (HUS) is a thrombotic microang

287 family of cytotoxic proteins that can cause hemolytic-uremic syndrome (HUS), a thrombotic microangio

288 Hemolytic-uremic syndrome (HUS), caused by Shiga toxin (

289 ions, including hemorrhagic colitis (HC) and hemolytic-uremic syndrome (HUS), which is the most commo

290 li (STEC) causes hemorrhagic colitis and the hemolytic-uremic syndrome (HUS).

291 thogens, responsible for bloody diarrhea and hemolytic-uremic syndrome worldwide.

292 ith defective regulation of the AP (atypical hemolytic-uremic syndrome) or with inadequate cleavage b

293 ding thrombotic thrombocytopenic purpura and hemolytic-uremic syndrome, have been reported to have a

294 ogen and is the cause of bloody diarrhea and hemolytic-uremic syndrome.

295 rrhagic colitis that sometimes progresses to hemolytic-uremic syndrome.

296 /14) with O157 strains (P = 0.03) developing hemolytic-uremic syndrome.

297 pathophysiology of neuronal complications in hemolytic-uremic syndrome.

298 in renal function in patients with atypical hemolytic-uremic syndrome.

299 erized member of a novel lipase family, is a hemolytic virulence factor that exhibits the most promin

300 ghly active against bacteria but also highly hemolytic, we found that replacing a small proportion of